Also known as: Long R3 IGF-1; approved relative: mecasermin
A long-acting modified IGF-1 used for muscle growth.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
Binds the IGF-1 receptor directly, driving muscle protein synthesis and glucose uptake.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Muscle & growth hormone | D | Animal or cell studies only |
At a glance
- Route
- Subcutaneous or intramuscular
- Half-life
- About 20 to 30 hours
Reported dosing
20 to 50 mcg daily (user reports).
Timing: After training.
Cycle: 4 weeks on, 4 off.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Low blood sugar (can be severe)
- Joint pain, headache
- Theoretical organ and tumor growth
Who should avoid it
- Any cancer history
- Diabetes medications
- Pregnancy
Often combined with
Rarely combined; risk of hypoglycemia rises with other GH-axis compounds.
Key findings
No human trials for this analog. Mecasermin (Increlex) is approved for severe primary IGF-1 deficiency in children.
Where it is legal (Oct 2026)
| US | Not approved |
|---|---|
| Canada | Not approved |
| Mexico | Not approved |
| EU | Not approved |
Sources
Open IGF-1 LR3 in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.